Saturday 21 December 2024
Internal Reference Number: FOI_8132
Date Request Received: 30/08/2024 00:00:00
Date Request Replied To: 18/09/2024 00:00:00
This response was sent via: By Email
Request Summary: Acute Myeloid Leukemia
Request Category: Health
| Question Number 1: 1. Please complete the table below with how many newly diagnosed patients with AML (Acute Myeloid Leukemia) have started first-line treatment with each of the following therapies during the 6-month period February 2024 to July 2024? Note: this should only include patients with AML who have started first-line treatment during the 6-month window Treatment option Number of newly diagnosed patients with AML starting first line treatment during the 6-month period February 2024 to July 2024 Azacitidine monotherapy LoDAC monotherapy Venetoclax + azacitidine Venetoclax + LoDAC Ivosidenib Intensive chemotherapy-based regimen (Examples include: cytarabine and daunorubicin, idarubicin, fludarabine, mitoxantrone, etoposide (VP-16), 6-thioguanine (6-TG), methotrexate (MTX) or 6-mercaptopurine (6-MP), gemtuzumab ozogamicin with daunorubicin cytarabine, or FLAG-Ida (fludarabine, cytarabine, granulocyte-colony stimulating factor and idarubicin) Best supportive care Other (Do not include prophylactic therapies such as GCSF, anti-fungals, antihistamines, anti-nauseants) | |
| Answer To Question 1: There have been less than 5 newly diagnosed patients during this period of whom have received the following treatments Venetoclax and LoDAC Intensive chemotherapy based regimens Best supportive care Responses for all other options would therefore be zero. | |
| To return to the list of all the FOI requests please click here |
Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
